At SCx CMC Solutions, we attend events like DCAT for a simple reason: if you want to understand where the pharmaceutical industry is actually headed, you have to pay attention to how people are talking when they’re deciding what to do next.
You can read headlines. You can watch the markets. You can track macro conditions. But pharma has always moved to its own rhythm — and that rhythm is often easier to hear in side conversations, industry gatherings, and off-agenda moments than it is in a quarterly report.
That felt especially true this year.
Because even with geopolitical instability, economic uncertainty, and plenty of noise outside the industry, the tone at DCAT 2026 felt more optimistic and more active than many people might have expected.
Not euphoric. Not reckless. But noticeably more engaged.
Here are three things the week made clear.
1 Pharma Is Moving Forward — Even in an Uncertain Market
One of the clearest takeaways from the week was that projects appear to be coming back online — even if many organizations are still waiting for the right moment to move.
As Ray put it, “There’s a lot of pent-up capital.”
That doesn’t mean the industry is moving without caution. It isn’t. But it does suggest that many organizations are no longer sitting entirely on the sidelines. There was a noticeable sense that teams are planning, evaluating, and getting ready to act.
That’s part of what makes pharma such a unique industry to read from the outside. Broader economic pressure absolutely affects it. So do geopolitical tensions, supply chain instability, and investor sentiment. But pharma rarely reacts on the same timeline as more trend-sensitive sectors. Programs take years. Decisions are layered. And development momentum doesn’t always stop just because the broader environment gets noisier.
As Kevin put it, “Pharma moves to its own rhythm.”
That rhythm showed up in a few ways throughout the week: projects are beginning to come back online capital doesn’t feel absent so much as held and long-running conversations around onshoring continue to shape how organizations are thinking about risk, resilience, and long-term manufacturing strategy
That’s part of why events like DCAT still matter. In an industry that doesn’t always move in a straight line — or on a predictable public timeline — some of the clearest signals come from listening closely before the shift is obvious from the outside.
2 How Pharma Outsourcing Decisions Actually Get Made
One of the strongest reminders of that came before the conference floor fully got going: the first-ever SOPPhC Sidebar hosted by the Society of Pharmaceutical Consultants (SOPPhC) on Monday evening.
SCx is proud to support the SOPPhC because experienced consultants play an important role across pharmaceutical development, manufacturing, and outsourcing — often helping organizations navigate high-stakes decisions with deeper technical context and greater flexibility.
The event was a strong kickoff to the week and a reminder that many of the conversations shaping pharma strategy, partnerships, and outsourcing decisions are already underway long before a formal decision is made.
That matters because outsourcing decisions are rarely as simple as they look on paper.
In many cases, the people ultimately responsible for making those decisions may not be the most technically equipped to evaluate every capability, every tradeoff, or every proposed path forward on their own. That’s where experienced consultants often play a critical role — helping companies ask better questions, assess whether a partner can actually deliver, and bridge the gap between technical reality and business urgency.
Technical judgment and decision-making authority do not always sit in the same place. That’s one reason experienced consultants can play such an important role in helping organizations assess fit, feasibility, and risk before a path is chosen.
That’s part of what made the mix at the SOPPhC event so meaningful. Seeing consultants, industry partners, and organizations like Piramal and CDMO World in the same space reflected something real about how modern outsourcing decisions actually happen: through expertise, trust, interpretation, and repeated interaction over time.
It was also great to connect with the CDMO World team in person — another reminder that the conversations shaping this industry don’t end when the event does. Both Ray Sison and Kevin Bittorf contribute columns to CDMO World, and we’re looking forward to seeing more stories and reflections from the week continue to unfold there.
3 What Pharma Companies Are Getting Wrong About AI Adoption
If there was one topic that followed us through nearly every corner of the week, it was AI.
Not in a neat, settled way — more in the sense that everyone knows it matters and no one wants to be behind.
As Ray put it, “Everyone’s trying not to miss the AI bus.”
That energy is real. Across conversations, the same question kept surfacing in different forms: “What are you doing with AI?”
And underneath that question was something even more familiar: FOMO without operational clarity.
A lot of organizations clearly feel pressure to act. But in many cases, that pressure is getting ahead of the strategy. Teams are buying tools before identifying use cases. They’re exploring platforms before fully understanding where their actual workflow pain lives. They’re trying to build “AI strategy” from the outside in.
That’s risky in any industry. In CMC, it’s especially risky.
This is a highly specialized, highly regulated environment. Workflows are technical. Review burdens are real. Documentation is complex. And the friction points that actually slow teams down are often much more specific than generic software messaging would suggest.
The most useful AI conversations right now shouldn’t begin with “What can this tool do and how do we use it?”
It starts with questions like:
- Where is our workflow losing time?
- Where are review cycles stalling?
- Where is information fragmented?
- Where are we repeating work that should be easier to interpret, organize, or execute?
- Can we find an existing AI solution to solve these problems or do we need to create one?
That’s what strategic implementation actually looks like.
In regulated, technical environments, useful AI adoption should begin with workflow logic — not trend pressure.
And importantly, this is no longer the moment for companies to hope they’ll “strike gold” just by hopping on the trend early. That phase — where early experimentation sometimes paid off simply because the market was moving so fast — is fading. What comes next is less glamorous, but much more valuable and sustainable: intentional, grounded implementation.
And honestly, that should be a relief.
Pharma already moves to the beat of its own drum. It doesn’t need to start chasing every passing technology cycle like it’s selling seasonal fashion. The opportunity now is not to move frantically. It’s to move thoughtfully enough that the work actually gets better.
That’s how SCx approaches AI conversations: not by starting with the tool, but by starting with the work.
What SCx Is Taking Away from DCAT 2026
DCAT 2026 reinforced something important: even in a noisy and unsettled environment, this industry is still moving.
The shifts may not always announce themselves all at once. But they’re there — in the return of project activity, in the continued focus on outsourcing and onshoring strategy, and in the growing pressure to turn AI from buzzword into something genuinely useful.
For SCx, the value of a week like DCAT is not just in what gets said publicly. It’s in paying attention to how priorities are changing, where confidence is building, and which conversations are starting to carry more weight.
Because in this industry, by the time a shift becomes obvious, the real work of shaping it is often already well underway.
